Actively Recruiting
Biomarkers in Autoimmune Disease of Nervous System
Led by Tongji Hospital · Updated on 2024-11-20
50000
Participants Needed
1
Research Sites
152 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Neurological autoimmune diseases are a group of disorders characterized by the abnormal immune response attacking the nervous system, including the brain, spinal cord and peripheral nerves. These diseases exhibit high heterogeneity, diverse clinical presentations, and are challenging to diagnose and manage due to a lack of effective treatments. In this study, the investigators will recruit eight kinds of autoimmune diseases of nervous system including Neuromyelitis Optica Spectrum Disorder (NMOSD), Myasthenia Gravis (MG), Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), idiopathic inflammatory myopathy (IIM), and multiple sclerosis (MS), autoimmune encephalitis (AE), Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD). Through this study, the investigators aim to discover biomarkers with high sensitivity, specificity, and stability, which can support early diagnosis, disease monitoring, and personalized treatment for neurological autoimmune diseases, thereby improving the quality of life and prognosis for patients.
CONDITIONS
Official Title
Biomarkers in Autoimmune Disease of Nervous System
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Clinical diagnosis with autoinflammatory diseases of the nervous system, including Neuromyelitis Optica Spectrum Disorder, Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, idiopathic inflammatory myopathy, multiple sclerosis, autoimmune encephalitis, Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease, and others
- Sex- and age-matched healthy individuals
You will not qualify if you...
- Known history of primary immunodeficiency (innate or acquired)
- Severe central nervous system, pulmonary, or other systemic infections
- Secondary central nervous system demyelinating lesions caused by vasculitis, systemic lupus erythematosus, or Sj�f6gren's syndrome
- Vascular (hemorrhagic or ischemic), hereditary metabolic, neoplastic, or toxic diseases
- Pregnant or lactating women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China, 430030
Actively Recruiting
Research Team
L
Luo-qi Zhou, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here